Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 6,300 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Forward revenue growth (NTM) 
